AbbVie Inc. — Director's Dealing 2025

Jan 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2024-12-31

Reporting Person: Alpern Robert J (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-31	Stock Equivalent Units	$177.70	A	42	Acquired		Common Stock (42)	Direct

Footnotes

F1: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.